Print

Probiodrug AG Funds Brigham and Women's Hospital’s Research Into Antibody Targeting Pyroglutamated Abeta For Treatment Of Alzheimer’s Disease  
12/23/2013 9:26:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HALLE/SAALE, Germany--(BUSINESS WIRE)--Probiodrug AG (Probiodrug) announced today the decision to provide research funding to the laboratory of Cynthia Ann Lemere, Ph.D., in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical School in Boston, MA. Funded by the National Institutes of Health (NIH), Dr. Lemere is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been correlated with cognitive decline in individuals with Alzheimer’s disease. The funding provided by Probiodrug will be used to expand this work to include additional research aimed at understanding mechanisms of clearance using several experimental anti-pGlu Abeta monoclonal antibodies (mAb) provided by Probiodrug.

Help employers find you! Check out all the jobs and post your resume.

//-->